|Last Price||Today's Change||52-Week Range||Trading Volume|
|113.07||-0.38 (-0.33%)||81.56 - 119.70||2.4 million (Below Avg)|
Market data as of 4:00PM 12/04/13. Quotes are delayed by at least 15 min.
U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
11/22/2013 5:30 PM ET